Equities Analysts Issue Forecasts for Cybin FY2026 Earnings

Cybin Inc. (NASDAQ:HELP) – Analysts at HC Wainwright lowered their FY2026 EPS estimates for Cybin in a report released on Monday, March 2nd. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($4.42) per share for the year, down from their previous estimate of ($3.02). HC Wainwright has a “Buy” rating and a $95.00 price objective on the stock. HC Wainwright also issued estimates for Cybin’s Q4 2026 earnings at ($1.04) EPS, FY2027 earnings at ($3.04) EPS, FY2028 earnings at ($1.49) EPS, FY2029 earnings at $0.87 EPS and FY2030 earnings at $4.18 EPS.

Separately, Jefferies Financial Group initiated coverage on shares of Cybin in a research report on Monday, February 2nd. They issued a “buy” rating and a $22.00 target price on the stock. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $58.50.

Cybin Stock Performance

Shares of HELP opened at $5.25 on Thursday. The stock has a market capitalization of $262.87 million, a P/E ratio of -1.24 and a beta of 0.61. Cybin has a 1-year low of $4.81 and a 1-year high of $9.83.

Cybin (NASDAQ:HELP) last released its quarterly earnings data on Friday, February 13th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.19).

More Cybin News

Here are the key news stories impacting Cybin this week:

• Positive Sentiment: Topline Phase 2 result: Company reported a statistically significant signal detection for HLP004 in GAD — a clear clinical milestone that validates the program and supports further development. Helus Pharma Topline Release
• Positive Sentiment: Analyst long-term thesis remains in place: Coverage notes (and a published price-target raise) reflect continued bullish long-term scenarios for HELP based on pipeline potential and longer-horizon earnings upgrades. Price Target Raised to $95
• Neutral Sentiment: Full results/transcript posted: Management commentary and the Phase 2 prepared remarks were published; investors will parse the detailed readout, statistical methods, effect sizes and secondary endpoints before re-pricing. Seeking Alpha Transcript
• Neutral Sentiment: Data reporting / market metrics flagged as noisy: recent short-interest reporting in public summaries appears inconsistent/unchanged (data shows zeros/NaN), so short-interest signals are not currently informative to explain price moves.
• Negative Sentiment: Market reaction: Despite the positive topline, the stock fell as some investors viewed the announcement as a limited “signal detection” readout rather than a full efficacy result (questions about magnitude, secondary endpoints, sample size and next steps drove selling). Yahoo Finance: Stock Down After Data
• Negative Sentiment: Near-term estimates trimmed: HC Wainwright and other notes reduced near-term (Q4 2026 / FY2026–2027) EPS forecasts even as they kept a bullish long-term view — weaker short-term numbers can pressure the stock while development continues. MarketBeat HELP profile (analyst note summary)

About Cybin

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.